Regulatory Compliance at Regenex Asia
Regenex Asia operates under full approval from the Malaysian Ministry of Health (KKM) as a licensed cell therapy laboratory. Our operations are not self-regulated — they are overseen by a national health authority with the power to inspect, audit and enforce compliance.
What KKM Approval Means
- Our facility meets Malaysian regulatory requirements for cell therapy manufacturing
- Our quality management system has been assessed and approved
- Our manufacturing processes operate within validated parameters
- Our personnel are qualified and trained to regulatory standards
- Our products are manufactured, tested and documented in compliance with applicable standards
Malaysian Regulatory Landscape
Malaysia has developed a regulatory framework for cell therapy that balances patient access with quality oversight — encompassing facility licensing, cGMP requirements, clinical trial protocols and guidelines for clinical application of cellular products.
International Regulatory Context
Patients from regulated markets (US, EU, UK, Australia, Singapore) should understand that Regenex products are regulated under Malaysian law and KKM oversight. They do not individually hold FDA, EMA, MHRA, TGA or HSA approval.
Our cGMP manufacturing standard is equivalent to the quality framework required in these jurisdictions, but the regulatory approval pathway is different. We are transparent about this distinction.